21 May 2013
Keywords: Pfizer, Vfend, Eraxis, Fungal infections, Ph III
Article | 03 October 2011
There was disappointing news for global drugs behemoth Pfizer (NYSE: PFE) last Friday, when the company reported top-line results from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
3 October 2011
2 October 2011
20 May 2013
© 2013 thepharmaletter.com